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Background: Statins are effective for primary prevention of cardiovascular (CV) disease, the leading cause of death
in the world. Multinational guidelines emphasize CV risk as an important factor for optimal statin prescribing.
However, it’s not clear how primary care providers (PCPs) use this information. The objective of this study was to
determine how primary care providers use information about global CV risk for primary prevention of CV disease.
Methods: A double-blinded, randomized experiment using clinical vignettes mailed to office-based PCPs in the
United States who were identified through the American Medical Association Physician Masterfile in June 2012.
PCPs in the control group received clinical vignettes with all information on the risk factors needed to calculate
CV risk. The experimental group received the same vignettes in addition to the subject’s 10-year calculated CV risk
(Framingham risk score). The primary study outcome was the decision to prescribe a statin.
Results: Providing calculated CV risk to providers increased statin prescribing in the two high-risk cases (CV risk >
20%) by 32 percentage points (41% v. 73%; 95% CI = 23-40, p <0.001; relative risk [RR] = 1.78) and 16 percentage
points (12% v. 27%, 95% CI 8.5-22.5%, p <0.001; RR = 2.25), and decreased statin prescribing in the lowest risk case
(CV risk = 2% risk) by 9 percentage points [95% CI = 1.00-16.7%, p = 0.003, RR = 0.88]. Fewer than 20% of
participants in each group reported routinely calculating 10-year CV risk in their patients.
Conclusions: Providers do not routinely calculate 10-year CV risk for their patients. In this vignette experiment,
PCPs undertreated low LDL, high CV risk patients. Giving providers a patient’s calculated CV risk improved statin
prescribing. Providing PCPs with accurate estimates of patient CV risk at the point of service has the potential to
improve the efficiency of statin prescribing.
Keywords: Primary prevention, Cardiovascular disease, Statins, Cardiovascular riskBackground
Cardiovascular (CV) disease is the leading cause of death
in the world, with coronary artery disease alone resulting
in over 7 million deaths annually [1]. HMG-CoA reduc-
tase inhibitors, or statins, are among the most effective
and widely used treatments for reducing CV morbidity
and mortality. Although there are substantial differences* Correspondence: nishants@umich.edu
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reproduction in any medium, provided the orbetween recommendations for when and how to use
statins for primary CV prevention, virtually all multi-
national clinical guidelines recommend estimating a pa-
tient’s overall CV risk in clinical decision making [2,3].
Although past guidelines for primary CV prevention in
the U.S., including the ATP III NCEP III guideline, (3)
have focused on specific lipid targets (i.e., a “treat to
target” approach), there is increasing evidence for and
interest in basing treatment primarily on overall CV risk
[4]. Even ATP III guidelines base the individual patient’s
recommended low-density lipoprotein cholesterol (LDL-
C-C) goal on their overall CV risk, and it is likely that CVl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ATP IV guidelines. This is because recent evidence dem-
onstrates how “tailoring” statin treatment based directly
on the patient’s overall CV risk and expected benefit from
a given statin dose can be a much more efficient approach
than using LDL-C targets, preventing many more CV
events while using less medication [5]. Although the
greater efficacy of this type of benefit-based tailored
(BTT) approach has gone almost completely unopposed
scientifically, some critics have suggested that an approach
so heavily based on CV risk is too complicated to be
effectively implemented [6].
Current research suggests providers believe knowing a
patient’s overall CV risk is important [7]. However, in rou-
tine practice most providers do not regularly calculate CV
risk, estimate risk inaccurately, and tend to ignore impor-
tant variations in CV risk [8-13]. Two potential reasons
for this are 1) clinicians believe they can “gestalt” a pa-
tient’s CV risk, and 2) the amount of time it would take
clinicians to do the calculation is a barrier. In the era of
the electronic medical record, it is possible to automate
estimates of patient’s overall CV risk for the clinician, as is
now often done for the kidney glomerular filtration rate
(GFR), and efficiently integrate this information into cli-
nical workflow.
There has been limited research on the effect of CV
risk presentation on primary care physicians’ (PCPs) pri-
mary CV prevention practices [14,15]. These studies
suggest that explicit CV risk presentation may modestly
improve provider prescription practices with regards to
lipid lowering therapy. To our knowledge, none of these
studies addressed the issue of how providers respond to
clinical situations where LDL-C measurements are dis-
cordant from and are a poor reflection of a patient’s true
overall CV risk. Knowing how PCPs reconcile this di-
lemma is important because it provides needed insight
about how clinicians prioritize CV risk in statin treat-
ment decisions, and how a BTT approach to primary
CV prevention may be effectively implemented.
We examined this issue in a true experiment using cli-
nical vignettes, in which we randomized primary care pro-
viders (PCPs) into two groups: a control group that
received clinical vignettes of patients with information on
their individual CV risk factors, and an experimental
group that received the identical cases in addition to indi-
vidual 10-year CV risk as determined by the Framingham
Risk Score [16], a validated tool to estimate cardiovascular
risk. We designed the clinical vignettes to include a wide
range of 10-year CV risk, and specifically included cases
where LDL-C values were normal but clinical risk was
moderate to high (situations in which some guidelines
would recommend no medication treatment). We hypo-
thesized that explicit presentation of the overall CV risk
calculation would improve the statin prescribing efficiencyamong PCPs—they would preferentially prescribe statins
to higher expected benefit rather than lower benefit
patients.
Methods
Experimental design
We used a double-blinded, randomized, controlled ex-
perimental design. All study subjects were provided with
an identical set of clinical scenarios, which included all
the information needed to calculate 10-year CV risk,
with the additional information of 10-year Framingham
CV risk estimates for individuals randomized to the ex-
perimental arm.
Setting and participants
We mailed surveys to a random sample of 1,500 office-
based adult primary care physicians (PCP) trained in
Internal Medicine or Family Medicine practicing in the
United States. We identified these providers through
random sampling of the American Medical Association
(AMA) Physician Masterfile, which contains practice in-
formation from 153,675 office-based internal medicine
and family physicians in the United States. We obtained
the data through the Direct Medical Data (DMD) Cor-
poration (Des Plaines, IL), after receiving approval from
The University of Michigan Institutional Review Board.
DMD randomly selected and assigned the study subjects
into an experimental or a control arm and provided the
research team with de-identified data files.Survey instrument and intervention
The survey consisted of several background questions
and 5 clinical vignettes, each containing a brief clinical
history, including all CV risk factors in the Framingham
risk score reported by D’Agostino and colleagues [16].
The clinical cases were designed to capture a range of
predicted CV risk and LDL-C values. We pilot tested the
surveys for clarity and content in a convenience sample
of physicians at our institution. The complete surveys
can be found in Additional file 1 (Control Group Sur-
vey) and Additional file 2 (Experimental Group Survey).
Study subjects received a $20 bill as a monetary incen-
tive. We sent a reminder postcard to survey respondents
one week prior to the requested due date. The data from
the returned surveys were abstracted and double-entered
into the study database.Outcomes
Our primary outcome was the likelihood of prescribing
a statin for each clinical vignette for the two treatment
arms (after a trial of diet and exercise), measured on a
five-point Likert Scale. Secondary outcomes included
estimation of 10-year CV risk among respondents in
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goals, and several questions about their clinical practice.
Statistical methods
We used a 2-sample independent groups t-test for our
main analysis comparing the likelihood of prescribing a
statin between our control and experimental arms for
each vignette. We used a 1-sample t-test to compare pre-
dicted control respondents’ estimates of vignette subjects’
10-year CV risk, comparing their estimate to the calcu-
lated Framingham risk scores. Our sample size of 626 re-
spondents (313 individuals in each arm) provides us with
80% power to detect a difference of 10 percentage points
between the control and experimental groups (0.2 v. 0.3,
two-sided testing with alpha = 0.05).
After conducting the main a priori analyses, we
performed a single post-hoc analysis of how a control
PCP’s estimate of the patient’s 10-year CV risk impacted
the probability that they would prescribe a statin for thatEnroll
Analy
Alloca
Office-Based Prov
Family Medicin
Internal Medici
Randomized
Allocated to Control group (n=750)
Family Medicine: n=392
Internal Medicine n=358
Follow
Returned Surveys (n=253)
Undeliverable Surveys: n=5
Non-response: n=495
Analy
Analyzed (n= 243)
Excluded from analysis:
Does not prescribe statins: n=6
Survey data double-entry not able to be 
performed: n=1
Not currently practicing primary care 
(deceased, war, other specialty): n= 3
•
•
•
Figure 1 Flow of respondents through the randomized experiment.case. All statistical analyses were performed using Stata
12 (College Station, TX).
Results
Characteristics of survey respondents
Of the 1500 PCPs sent surveys, a total of 520 responded
(35%). Figure 1 illustrates the flow of respondents.
Table 1 displays their characteristics and shows that the
control and intervention groups are well matched across
a range of attributes. Approximately two-thirds of the
survey respondents were family medicine trained, nearly
75% were in practice for 10 or more years, and the ma-
jority saw more than 40 patients per week (nearly half
seeing more than 80 patients).
Estimation of 10-year cardiovascular (CV) risk
A minority of respondents reported regularly calculating
10-year CV risk (<20% in each group). Control group PCP
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Table 1 Characteristics of survey respondents in the
analysis sample
Respondent characteristics Control
group
(n = 243)
Experimental
group
(n = 255)
Specialty
Family medicine 62.3 61.9
Internal medicine 37.7 38.1
Post-graduate practice years in an
outpatient setting
<5 years 5.9 6.4
5-10 17.0 16.3
>10 77.1 77.3
Number of patients seen/week
< 40 10.0 13.4
40-59 14.9 10.9
60-79 23.6 21.5
>80 51.5 54.3
Practice region
Northeast 18.2 17.1
Midwest 30.6 26.6
South 31 30.6
West 20.3 25.8
How often do you predict 10-year
cardiovascular risk in your patients?
Almost never or never 49.8 43.7
Sometimes 31.1 41.9
Almost always or always 19.1 14.4
I would allow a trained nurse or
member of my support staff to
address the issue of primary
prevention for coronary artery disease
with my patients through an
approved standard protocol?
Strongly disagree or disagree 13.6 15.2
Neither agree nor disagree 19.5 17.9
Agree or strongly agree 67.0 67.0
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1 and 3), PCPs overestimated CV risk by more than 9 per-
centage points (both P < 0.001). For example, Case #1′s
10-yr CV risk was only 2%, but over 75% of respondents
estimated her risk as being 9.5% or greater. In contrast,
for the two highest CV risk vignette patients (Cases #2
and #5, CV risks 21% and 22%, respectively), PCP mean
estimates were significantly underestimated, but were
within 5 percentage points of their Framingham score.
The combined effect of these under- and over-estima-
tions were striking, however. For example, although
Case # 2's 10-yr CV risk (21%) was 3-times higher thatCase #3 (7%), PCP estimates of these two vignette’s
CV risk were almost identical: 19.3% (interquartile
range [IQR] = 17.3%-21.3%) and 19.7 (IQR = 17.5-21.9),
respectively.
Impact of providing patient CV risk to PCPs on statin
prescribing
The control and experimental groups both prescribed
statins at the highest rates for the two patient vignettes
with the highest LDL-C values but the lowest overall
CV-risk (cases #1 and #3). In each of these cases, PCPs
in both arms prescribed statins >60% of the time. Fur-
ther, being informed that the 10-yr CV risk was low had
only a small, though statistically significant, 9 percentage
point absolute decrease in the likelihood of prescribing a
statin in both cases (P = 0.03 and P = 0.04, Table 3). In
contrast, for patients with relatively low LDL-C values
but with the highest CV-risks (Cases # 2 and 5, 10-yr
risks of 21% and 22%, respectively), providing PCPs with
overall CV risk estimates substantially increased statin
prescribing. In Case #2 (a 70 year old man with a 21%
10-year CV-risk), the proportion of PCPs prescribing a
statin increased from 41% to 73% with presentation of
risk (increase = 32 points [95% CI = 23-40]). Overall,
congruence with NCEP III recommendations were mo-
derate to high for Cases #4 & #5, but a majority of PCPs
diverged from NCEP III guideline recommendations by
recommending treatment in a low-risk woman with an
LDL of 135 (Case #3, see Table 3).
In a post hoc analysis of respondents in the control arm
(who were not given the calculated Framingham score),
we found that the higher a PCP’s estimate of 10-year CV
risk, the greater the likelihood they would prescribe a
statin. This means that those control physicians who
prescribed a statin in Cases #1 and #3 (high LDL-C/low
CV risk/low statin benefit) were those who most severely
over-estimated 10-year CV risk, and that those control
physicians who did not prescribe a statin in Cases #2
and #5 (low LDL-C/high CV risk/high statin benefit) were
those who most severely under-estimated 10-year CV risk
(Figure 2).
Discussion
Preventing cardiovascular (CV) disease morbidity and
mortality is among the most important public health pri-
orities in the United States and throughout the world,
and statins are highly effective for primary prevention
[17,18]. Selecting who should receive them, and at what
doses, have been the subject of various guidelines and
considerable debate. One consistent fact is that rando-
mized clinical trial evidence suggests that overall CV risk
is by far the largest determinant of how much absolute
benefit a patient will receive from a statin [5]. In this ex-
periment, we found providing PCPs with overall CV risk
Table 2 Clinical scenarios and associated 10-year CVD
risk estimates
Clinical scenario
(n = number
responding to the
question in the
control group)
Calculated
10-year
Framingham
risk for
coronary
artery
disease
Mean
predicted
10-year
cardiovascular
risk and
interquartile
range among
respondents
in the control
group*
(N = 243)
p-value for
differences
between
calculated
and mean
predicted
10-year
CVD risk
Case 1. A 52 year-old
woman with no chronic
conditions, no history of
tobacco or family
history of cardiovascular
disease; blood pressure
128/82, pulse 72, BMI
30; after a trial of diet
and exercise, total
cholesterol 260 mg/dL,
triglycerides 145 mg/dL,
HDL 56 mg/dL, and
LDL-C 175 mg/dL
(n = 235)
2 11.2 [9.5-12.8] <0.001
Case 2. A 70 year-old
man with hypertension,
treated with a thiazide,
and osteoarthritis. He
quit tobacco 40 years
ago; blood pressure
136/80, pulse 70; after a
trial of diet and
exercise, total
cholesterol 208 mg/dL,
triglycerides 190 mg/dL,
HDL 42 mg/dL, and
LDL-C 128 mg/dL
(n = 232).
22 19.3 [17.3-21.3] 0.007
Case 3. A 55 year-old
woman with
hypertension, treated
with a calcium channel
blocker, and obesity;
she smokes 1 pack of
cigarettes daily, and has
no family history of
cardiovascular disease
or diabetes; blood
pressure 128/82, pulse
72, BMI 32; after a trial
of diet and exercise,
total choleseterol is
200 mg/dL, triglycerides
125 mg/dL, HDL
40 mg/dL, and LDL-C
135 mg/dL (n = 233).
7 19.7 [17.5-21.9] <0.001
Case 4. A 52 year-old
man with hypertension,
treated with a thiazide;
he smokes 1 pack of
cigarettes daily, and has
no family history of
cardiovascular disease;
blood pressure is 128/
82, pulse 72; after a trial
13 16.7 [14.9-18.5] <0.001
Table 2 Clinical scenarios and associated 10-year CVD
risk estimates (Continued)
of diet and exercise,
total cholesterol is
145 mg/dL, triglycerides
125 mg/dL, HDL
30 mg/dL, and LDL-C
90 mg/dL (n = 231)
Case 5. A 71 year-old
man with hypertension,
treated with an ace
inhibitor, and benign
prostatic hyperplasia; he
quit tobacco 30 years
ago; blood pressure
136/80, pulse 70; total
cholesterol 178 mg/dL,
triglycerides 190 mg/dL,
HDL 44 mg/dL, and
LDL-C 96 mg/dL
(n = 228)
21 15.9 [14.3-17.5] <0.001
*Mean predicted 10-year CVD risk based on one-sample t-test.
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statins in high CV risk cases with “normal” LDL-C,
patients for whom there has been grade A evidence for
high benefit from a statin for the past decade [19]. We
found that PCPs substantially under-estimated the CV
risk of these low LDL-C patient vignettes, and this was
associated with substantial under-prescribing.
We also found that PCP’s prescribed statins at the
highest rates for the case with the lowest CV risk (2%) and
a high LDL-C. Whether this represents “over-treatment”
is a matter of debate. While the evidence suggests such a
patient is much less likely, compared to a higher risk
patient, to have averted a CV event over a 5-10 year
period, some lipid experts have argued for treatment
based upon the concept of elevated “lifetime risk” [20].
This might in part explain our finding that providing PCPs
with the overall CV risk for such a patient (low CV risk
with elevated LDL-C) only modestly reduced statin pre-
scribing in this case. Nonetheless, we did find that those
control PCPs who most severely over-estimated CV risk
in cases with high LDL-C were also the most likely to pre-
scribe a statin.
Our findings are similar to other studies finding infre-
quent calculation and inaccurate estimation of overall
CV risk [7-12]. While this alone was not surprising, the
magnitude of statin treatment intensity in both the con-
trol and experimental groups for lower risk vignettes in
the study (CV risk of 2% and 7%) were particularly strik-
ing in our national sample, contrasting with much lower
statin prescribing rates recently reported by PCPs at a
single academic center [15]. In addition, the relative in-
creases in treatment intensity in the experimental group
for the high risk vignettes (CV risk of 21% and 22%)
were much higher than in other studies of risk
Table 3 Physician recommendations for statin treatment by intervention group compared to NCEP III guidelines and a
tailored treatment approach
ATP III NCEP III
statin treatment
recommendation
Benefit based
therapy statin
treatment
recommendation
Proportion of
control group
prescribing
statin therapy
Proportion of
experimental
group prescribing
statin therapy
Mean difference*
[control -experimental
groups [95% CI]
P value
Case 1. 52 year-old
woman: 10-year risk, 2%;
LDL-C (175 mg/dL)
Optional No statin 0.76 0.67 0.09 [0.007, 0.167] 0.03
Case 2. 70 year-old man
male: 10-year risk, 22%;
LDL-C (128 mg/dL)
Optional High-potency
statin
0.41 0.73 −0.32 [-0.397, -0.231] <0.001
Case 3. 55 year-old
woman: 10-year risk, 7%;
LDL-C (135 mg/dL)
No Moderate-potency
statin
0.74 0.65 0.09 [0.003, 0.166] 0.04
Case 4. 52 year-old man:
10-year risk, 13%; LDL-C
(90 mg/dL)
No Moderate-potency
statin
0.20 0.26 −0.06 [-0.136, 0.132] 0.11
Case 5. 71 year-old man:
10-year risk, 21%; LDL-C
(96 mg/dL)
No High-potency
statin
0.12 0.27 −0.16 [-0.225, -0.085] <0.001
* Mean differences between control and experimental groups are representative as +/- numbers. Positive numbers favor statin treatment among respondents in
the control group, and negative numbers favor statin treatment among respondents in the intervention group.
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tent with, but cannot prove, that providers over-value
high and low LDL levels, resulting in over-estimating
CV risk in high LDL subjects and under-estimating risk
in low LDL patients.
The practice tendencies among PCPs in our study—of
infrequent use and inaccurate estimation of overall CV
risk, especially in light of the substantial under-treatment
of cases with high CV risk and low LDL-C —are con-
cerning. However, our study results suggest that these
practice patterns are potentially modifiable and highlight
opportunities for improvement. While we hope that our
results and those of others will lead to more physicians0
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Figure 2 Primary care providers’ probability of prescribing a statin bacalculating their patients’ CV risks (or having someone do
it for them), we are entering a new era of the electronic
medical record that offers even greater potential. Expe-
rience from point-of-service A1c results [23] and auto-
mated GFR estimates [24] demonstrate how care can be
substantially improved by providing PCPs with valuable
information at the point of service. Automating CV risk
prediction in a modern EHR has the potential to improve
CV prevention, not just regarding statin therapy, but for
other CV preventive care as well [25].
There are certain limitations of our study that merit par-
ticular note. We used the Framingham risk score, an
established cardiovascular risk score that has been widely30 40 50
cular Risk
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sed on their perception of estimated CV risk.
Sekaran et al. BMC Cardiovascular Disorders 2013, 13:90 Page 7 of 8
http://www.biomedcentral.com/1471-2261/13/90validated and cited in the medical literature [16,26]. How-
ever, this score uses a limited set of clinical variables and
may not capture all aspects of individual risk [27]. Pro-
viders should use the risk-prediction tool that has the best
evidence for accuracy and reliability in their population
[28]. Second, although common in physician studies, our
study had a low response rate. However, as a true experi-
ment, a low response rate is less likely to alter the experi-
mental findings – that providing PCPs with patient CV
risk estimates can reduce under-treatment. It could alter
the generalizability of our descriptive findings, particularly
the precise proportion of PCPs that calculate CV risk. Our
study evaluates the effect of presenting 10-year CV risk in-
formation on PCP statin prescribing, especially in cases
where LDL-C is at “target”, and is not designed to explain
how or why changes occurred. Third, these vignettes rep-
resent hypothetical scenarios and the answers may not
reflect providers’ actual practices. Previous studies have
established the validity of clinical vignettes for assessing
clinical decision-making [29,30]. These scenarios were se-
lected for clinical importance. By using the same scenarios
for every respondent, we improved study power.
This study raises important future research questions
about clinical decision-making for primary CV preven-
tion. More needs to be known about how providers
understand and use information about clinical risk in
their treatment decisions especially since evidence sug-
gests they value this information. Our study showed that
even after informing PCPs that a patient with an ele-
vated LDL had a very low 10-year CV risk, most pre-
scribed a statin. Further research can deconstruct the
dynamics of this complex decision making process in-
cluding provider attention to existing ATP III NCEP III
(and soon to be published ATP IV) guidelines, know-
ledge about LDL-C and CV disease pathogenesis, fami-
liarity with patient preferences for statin therapy, and
the role of adverse risks associated with this medicine
class.
Conclusion
In summary, our study found that providing calculated
CV risk information to PCPs improves their statin pre-
scribing practices for patients at the lowest and highest
CV risks. PCPs in this study were seldom explicit about
overall CV risk in their treatment decisions, and were
not able to reliably estimate CV risk. Their statin pre-
scribing patterns make clear that CV risk is not the
primary factor influencing their statin prescribing deci-
sions. Our results suggest, but cannot prove, that cli-
nicians preferentially “anchor” on LDL-C treatment
targets even when they diverge from overall CV risk. In-
corporating automated CV risk information into clinical
workflow processes, similar to other point-of-service
data, using health information technology is possibleand consistent with current standards of “meaningful use”
[31]. In addition, guidelines recommending risk-based ap-
proaches should be based on sound clinical evidence, and
not include other elements that would distract from the
goal of minimizing harm and maximizing therapeutic
benefit in individuals at moderate to high-risk of CV
disease.
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